Esperion Therapeutics Presented Positive Top-Level Results for Phase 2 of Trials

Esperion Therapeutics Inc (NASDAQ: ESPR) announced positive top-level results for Phase 2 of trials for triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin.

The trials, which lasted six weeks, have yilded positive data as the LDL-C levels reportedly decreased 64% as a result of the triple therapy compared to the placebo treatment. Additionally, the therapy proved effective at a 48% reduction of a high-sensitivity C-reactive protein (hsCRP) which is an important marker of underlying inflammatory response associated with cardiovascular diseases. There were also no difference between the trail therapy and placebo treatment in terms of serious adverse events, muscle-related adverse events nor discontinuations due to muscle-related adverse events.

"Patients in this study experienced nearly a 100 mg/dL drop in their LDL-C levels on the combo plus atorvastatin. These highly positive study results of the combination therapy demonstrate very robust and remarkably consistent LDL-C lowering with what appears to be optimal safety and tolerability," said Tim M. Mayleben, president and chief executive officer of Esperion.

The company plans to continue testing multiple drug therapies in order to come to a most effective and flexible treatment plan for doctors and their patients. As a result of the extremely positive results of Phase 2, Esperion’s stock has risen about 24% on Tuesday.

Ratings

Ratings
  • 40Views
  • 0Comments

Recommend to Friends

  • facebook
  • Twitter
  • google plus
  • pinterest
  • Digg
  • stumbleupon
  • Reddit
  • linkedin

Nikita Medvedev

Email: Nikita@financialinsiders.com

@Newsletter

Sign Up for Weekly Updates

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

Related Posts

23 Jun, 2017 106
26 Jun, 2017 76
03 Jul, 2017 62
19 Jul, 2017 57

Comments

There is no comment on this article